AB Science: AB Science renews its Standby Equity Facility (PACEO) with Société Générale

AB Science: AB Science renews its Standby Equity Facility (PACEO) with Société

                                               Paris, July 30^th 2014 - 5.45pm

                                                         Permanent Information

                                 AB Science renews its Standby Equity Facility
                                                 (PACEO) with Société Générale

AB Science SA (Euronext Paris -  FR0010557264 - AB), a pharmaceutical  company 
specialised in research, development  and commercialisation of protein  kinase 
inhibitors (PKI), hereby announced the renewal of its Standby Equity  Facility 
(PACEO®) with Société Générale as  authorized by the Shareholders' Meeting  of 
June 27, 2014.

Commenting on this announcement,  Laurent Guy, Chief  Financial Officer of  AB 
Science has stated that: "Even  though we do not  currently need it since  our 
cash position is above 25 million euros, this equity financing facility allows
the diversification of our financial resources  and is a flexible solution  to 
finance potential new developments".

Under the terms of the agreement,  Société Générale has committed to  purchase 
newly created shares at any time during the 36-month commitment period, within
the global limit  of 3,200,000  shares, being  9.7% of  the 32,925,187  shares 
currently outstanding.

Should the entire standby equity facility  be drawn down and resulting in  the 
issuance of 3,200,000 new shares, a  shareholder who currently owns 1% of  the 
company's share capital would experience a reduction of his / her ownership to

For each tranche,  the price  to be paid  equals the  volume weighted  average 
share price of the three trading days preceding the effective date of purchase
with a discount  capped at  5% dependent  on the  size of  the drawdown.  This 
discount allows  Société  Générale, who  is  not  positioned as  a  long  term 
shareholder in the  Company, to  purchase the shares  independently of  market 

ABScience has no minimum  drawdown obligation, and will  use the facility  at 
its sole  discretion  if market  conditions  are  favorable and  in  the  best 
interests of both the Company and its shareholders.

About AB Science

Founded in 2001, AB  Science is a pharmaceutical  company specializing in  the 
research, development  and  commercialization  of  protein  kinase  inhibitors 
(PKIs), a new class of targeted molecules whose action is to modify  signaling 
pathways within cells. Through these  PKIs, the Company targets diseases  with 
high unmet medical needs (cancer,  inflammatory diseases, and central  nervous 
system diseases),  in both  human  and veterinary  medicines. AB  Science  has 
developed  a  proprietary  portfolio  of  molecules  and  the  Company's  lead 
compound, masitinib, has  already been registered  for veterinary medicine  in 
Europe and in  the USA,  and is  pursuing thirteen  phase 3  studies in  human 
medicine in first-line and second-line GIST, metastatic melanoma expressing JM
mutation of c-Kit, multiple myeloma, metastatic colorectal cancer,  metastatic 
prostate cancer, pancreatic  cancer, mastocytosis,  severe persistent  asthma, 
rheumatoid arthritis,  Alzheimer's  disease,  progressive  forms  of  multiple 
sclerosis, and Amyotrophic Lateral Sclerosis. The company is headquartered  in 
Paris, France, and listed on Euronext Paris (ticker: AB).

More information is available on our website: www.ab-science.com.

About PACEO®

The PACEO®  is an  equity  financing solution  that  was designed  by  Société 
Générale. The PACEO® helps issuers to diversify their funding sources  through 
an additional financing option, while  preserving the financial balances.  The 
PACEO® may be  drawn at  the issuer's  sole discretion  via the  issue of  new 
shares at a low discount to the then market price; this solution provides  the 
same benefits as a  capital increase while providing  the same guarantee as  a 
confirmed credit line.  With this transaction,  Société Générale, the  leading 
institution for equity lines in France, has set up its 42^th PACEO®.


[1]Based on 32,925,187 shares representing ABScience share capital

AB Science EN


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: AB Science via Globenewswire
Press spacebar to pause and continue. Press esc to stop.